
































































Screening for Hepatocellular Carcinoma among adults with
HIV/Hepatitis B coinfection in Zambia: A Pilot Study
C. Riebensahm , H. Chitundu , G. Muula , B. Chihota , E. Sinkala ,
V. Sunkutu , M.H. Maurer , JF. Dufour , A. Berzigotti , M. Egger ,





To appear in: International Journal of Infectious Diseases
Received date: 23 April 2021
Revised date: 14 December 2021
Accepted date: 15 December 2021
Please cite this article as: C. Riebensahm , H. Chitundu , G. Muula , B. Chihota , E. Sinkala ,
V. Sunkutu , M.H. Maurer , JF. Dufour , A. Berzigotti , M. Egger , C. Bolton-Moore , M. Vinikoor ,
G. Wandeler , IeDEA-southern Africa, Screening for Hepatocellular Carcinoma among adults with
HIV/Hepatitis B coinfection in Zambia: A Pilot Study, International Journal of Infectious Diseases
(2021), doi: https://doi.org/10.1016/j.ijid.2021.12.338
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition
of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of
record. This version will undergo additional copyediting, typesetting and review before it is published
in its final form, but we are providing this version to give early visibility of the article. Please note that,
during the production process, errors may be discovered which could affect the content, and all legal
disclaimers that apply to the journal pertain.
© 2021 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/)
Highlights 
 Hepatitis B virus infection is the main cause of liver cancer in Sub-Saharan Africa  
 Little is known about the incidence among individuals on antiretroviral therapy  
 This is among the first initiatives for liver cancer screening in the region  
 2% of HIV/hepatitis B Virus-coinfected adults had significant liver lesions 
 A quarter had findings suggestive of schistosomiasis-induced liver damage 
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Background & Aims: Chronic hepatitis B virus (HBV) infection is the main cause of 
hepatocellular carcinoma (HCC) in sub-Saharan Africa (SSA). In an established cohort of 
HIV/HBV-coinfected individuals on antiretroviral therapy (ART), we piloted an HCC screening 
initiative at two outpatient clinics in Lusaka, Zambia.  
Methods: We performed abdominal ultrasound (AUS) and transient elastography in all 
patients.  
Results: Among 279 HIV/HBV-coinfected patients, 165 (59.1%) were men, median age was 
34 years (interquartile range 28-39) and median CD4 count 246 cells/µl (112-355). While 102 
(36.6%) individuals had elevated transaminases, 114 (40.9%) had HBV levels >2000 IU/mL 
and 59 (24.6%) significant fibrosis. On AUS, 75 (26.9%) participants had hepatomegaly and 
69 (24.7%) peri-portal fibrosis. Five patients had a liver lesion >1cm, an indication for 
confirmatory imaging.  
Conclusions: In one of the first HCC screening initiatives in SSA, 2% of HIV/HBV-coinfected 
adults had significant liver lesions, and a quarter had findings suggestive of schistosomiasis-
induced liver damage. 
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Introduction 
Chronic hepatitis B Virus (HBV) infection is the single most important cause of end-stage 
liver disease and hepatocellular carcinoma (HCC) worldwide (Akinyemiju et al., 2017). Its 
burden is particularly high in sub-Saharan Africa (SSA), where approximately 10% of the 
general population has chronic HBV infection (Schweitzer et al., 2015, Yang et al., 2017). 
Several additional factors, such as the environmental exposure to aflatoxin B1, HIV co-
infection and unhealthy alcohol use, are frequent and might exacerbate the risk of HCC in 
HBV-infected individuals in the region (Kew, 2003, Nikolopoulos et al., 2009, Nouaman et al., 
2018). According to the World Health Organization (WHO), the elimination of HBV as a 
public health problem by 2030 requires a 65% reduction in hepatitis-related mortality, which 
is mainly driven by HCC (WHO, 2017). However, due to the lack of diagnostic capacity and 
incomplete cancer registries, epidemiological data on the incidence of HCC from SSA are 
scarce. 
The early diagnosis of HCC is key to reduce HBV-related mortality and can be achieved with 
the implementation of screening programs using 6-monthly abdominal ultrasound (AUS) 
measurements. If hepatic lesions are detected during AUS, further diagnostic procedures, 
including 4-phase computer tomography (CT), or repeat AUS, are needed to confirm the 
diagnosis, depending on the size of the lesions (European Association for the Study of the 
Liver, 2018). Although the presence of liver cirrhosis is the most important risk factor for 
developing HCC among people with chronic HBV, age, ethnicity and the presence of 
additional risk factors play a role. Current international guidelines recommend HCC 
screening for all HBV-infected patients of African origin after the age of 20 years, 
independent of the presence of cirrhosis (European Association for the Study of the Liver, 
2018). Importantly, data on HCC incidence and risk factors among HIV/HBV-coinfected 
         
individuals on tenofovir-containing antiretroviral therapy (ART) are very limited: in a large 
study from Europe, age at initiation of tenofovir was the most important predictor of this 
outcome besides cirrhosis (Wandeler et al., 2019). However, given the low number of 
patients of African origin included in the study, it remains unclear if the same risk factors 
should guide clinical decision on eligibility for HCC screening in African HIV clinics.  
In light of the many structural challenges affecting health care systems in SSA, the collection 
of primary HCC incidence data is key to inform risk stratification and eligibility for HCC 
screening.  Within a long-term prospective cohort of HIV/HBV-infected individuals at two 
primary care clinics in urban Zambia, we established an ultrasound-based pilot HCC 
screening program. Here, we present the results of the first ultrasound measurement from 
all patients included in the screening program and describe the main characteristics of 
individuals with at least one significant liver nodule. 
 
Methods 
Study population  
Beginning in 2013, we enrolled consecutive adults (18+ years) with HIV/HBV-coinfection into 
a prospective cohort study at two public sector outpatient primary care clinics in Lusaka, 
Zambia (Vinikoor et al., 2017). All participants were HBsAg-positive (Alere Determine, 
Waltham, MA) and initiated tenofovir disoproxil fumarate (TDF)-containing ART, as per 
standard of care in Zambia. Starting in January 2015, we invited all participants to join our 
pilot HCC screening program. The University of Zambia (Lusaka) and the University of 
Alabama at Birmingham ethics committees approved the protocol and all patients signed an 
informed consent to participate in the study.  
Study procedures  
         
Detailed information on demographic and clinical characteristics, as well as laboratory 
measurements were collected prior to ART initiation and at 3 to 6-monthly intervals 
thereafter, using standardized data collection forms. The following laboratory tests were 
performed at least yearly: full blood count, alanine aminotransferase (ALT; normal <19U/L 
for women and <30 for men), creatinine, CD4+ cell count and hepatitis B e-antigen (HBeAg). 
HBV viral load (VL) was measured yearly using the COBAS AmpliPrep/ COBAS Taqman 
platform (version 2.0 Roche Molecular Systems, Pleasanton, CA). We screened for the 
presence of anti-HCV antibodies using a rapid test (OraQuick, OraSure Technologies, 
Bethlehem, PA) (Wandeler et al., 2016). Alpha-Fetoprotein (AFP) was measured in all 
participants with available stored serum samples at time of first AUS. The AUDIT-C questions 
were used to assess alcohol consumption levels, and unhealthy alcohol use was defined as 
an AUDIT-C score > 3 for women and > 4 for men. Liver stiffness was measured annually 
using transient elastography (TE, Fibroscan 402, Echosens, Paris, France) and results were 
categorized according to the Metavir liver fibrosis stage: F0-F1 if LSM <7.1kPa, F2-3 if 7.1-
11kPa, F4 if >11.0kPa, as established previously (WorldHealthOrganization, 2015). An 
examination was deemed successful if at least 10 valid liver stiffness measurements (LSM) 
were obtained and it was considered very reliable if the interquartile range divided by 
median (IQR/M) was <0.1, reliable if IQR/M was 0.1–0.3, and poorly reliable if IQR/M was 
>0.3 (Boursier et al., 2013). 
HCC surveillance protocol  
In line with international recommendations, in January 2015, we asked participants to join 
our pilot HCC screening program und started to perform abdominal ultrasound imaging in all 
HIV/HBV-coinfected individuals (European Association for the Study of the Liver, 2018). As 
ultrasound imaging at cohort clinics was inconsistent, we transported patients to the 
         
University Teaching Hospital (UTH), Lusaka’s main referral hospital, located ~8 km away. 
Ultrasound examinations were performed in the early afternoon, prior to lunch, by one of 
three experienced radiographers at the Department of Radiology. The following 
characteristics were described using a standardized case-report form: liver mid-axillary 
diameter; portal vein diameter; presence of splenomegaly, ascites, intra-abdominal 
lymphadenopathy, and peri-portal fibrosis. Liver cirrhosis was diagnosed in the presence of 
at least one of the following: surface nodularity, overall coarse and heterogeneous 
echotexture, atrophy or segmental hypertrophy. Liver steatosis was diagnosed in the 
presence of increased echogenicity in comparison to the right kidney parenchyma and beam 
attenuation. Liver lesions were described in numbers, quality (hypo-, hyper-, or of mixed 
echogenicity), location, and the largest lesion was measured (in cm). When a liver nodule >1 
cm was documented on AUS, a 4-phase CT scan was performed at UTH. The LI-RADS system 
was used to standardize the interpretation and reporting for diagnostic imaging (LI-RADS®, 
Version 2017).  
 
Results 
Patient Characteristics  
Of 303 adults with HIV/HBV-coinfection enrolled in our cohort with a visit after January 
2015, 279 (92.1%) had at least one AUS measurement. Median age of participants was 34 
years (interquartile range [IQR] 28-39), and 40.9% were female. At initiation of ART, 118 
(42.6%) participants reported unhealthy alcohol use, 53 (19%) were smokers, and 30 (10.8%) 
were overweight or obese (body mass index >25.5). The median CD4 count was 246 cells/µL 
(IQR 112-355) and 100 (37.3%) had a WHO clinical stage 3 or 4 at ART initiation. Of all 
individuals with available data at the time of ART initiation, 102 (55.7%) had elevated ALT 
         
levels, 114 (59.7%) had HBV DNA levels >2,000 IU/ml, and 103 (38.0%) had a positive HBeAg 
test. Overall, 59 (24.6%) participants had a liver stiffness measurement compatible with 
significant fibrosis (Metavir ≥F2), of whom 16 (6.7%) had liver cirrhosis (Metavir F4). Of 147 
patients with measured AFP levels, three had AFP levels way above 20ng/ml. 
 
Liver ultrasound findings  
At their first AUS, participants had been on tenofovir-containing ART for a median of 8 
months (IQR 0-16). Efavirenz was the third agent for 97.1% of participants, whereas 2.9% 
were receiving a nevirapine-based ART regimen. In this cross-sectional analysis, 75 (26.9%) 
participants had hepatomegaly and 69 (24.7%) periportal fibrosis, whereas 6 individuals 
(2.2%) had signs of cirrhosis, and 4 (1.4%) had liver steatosis (Figure 1). Only one of 16 
individuals with liver stiffness compatible with cirrhosis had signs of liver cirrhosis on 
ultrasound. Liver lesions ≥1 cm were documented in five (1.8%) patients, mostly appearing 
with hyperechoic pattern (Figure 2, Panel A). One patient had multiple lesions. All 
participants with liver lesions were male and aged <50 years, two were HBeAg-positive, four 
(80.0%) had elevated ALT levels and two had HBV DNA levels >2000 IU/ml at ART initiation. 
None of the five individuals with liver lesions showed an elevated AFP level at time of AUS. 
According to the updated EASL nomenclature, one individual would have been classified as 
HBeAg-positive chronic HBV infection (patient 1), three as HBeAg-negative chronic HBV 
infection (patients 2-4), and one as HBeAg-positive chronic hepatitis (patient 5). At the time 
of their first ultrasound measurement, all five patients had a HBV VL <100 IU/ml. 
Two patients with focal lesions >1cm (patients 1 and 5, Figure 2A) were referred for further 
investigation by 4-phase CT scan. According to the LI-RADS categorization, lesions from both 
patients had a low probability of HCC on CT scan.  Figure 2B shows radiological examinations 
         
of patient 5, who had an HBeAg-positive chronic hepatitis B with a high viral load at baseline 
and liver cirrhosis. On ultrasound, a heterogeneous echotexture, surface nodularity of the 
liver and multiple focal hypo- and hyperechoic focal lesions were noted. On 4-phase CT scan, 
these lesions did not present any diagnostic HCC hallmarks, and were most likely 
hemangiomas. In two participants, there was a delay in recognizing the need for CT and on 
the next AUS liver lesions were no longer visible (patient 3) or had decreased in size (patient 
4). Finally, one patient withdrew from the study for personal reasons before a CT could be 





Within a cohort of HIV/HBV-coinfected individuals in Zambia, we successfully engaged 279 in 
one of the first liver cancer screening initiatives for HBV-infected persons in SSA. At their first 
assessment, about 2% of our patients had a liver lesion that warranted further diagnostic 
testing with a 4-phase CT scan. Given the high proportion of participants with active 
hepatitis B, unhealthy alcohol use, and peri-portal fibrosis suggestive of schistosomiasis-
induced liver damage, our findings highlight the need for the continued evaluation of HCC 
incidence in this population.  
Our study demonstrated that imaging-based screening for HCC is feasible in resource-
constrained settings, provided there is dedicated staff, skilled radiologists and access to 
adequate infrastructure. AUS were straightforward to perform at the referral center; 
however, having de-centralized and integrated access to AUS at front-line facilities would 
further increase feasibility. Although our study population consisted mainly of young 
HIV/HBV-coinfected individuals on tenofovir-containing ART, a significant proportion had 
relevant risk factors for the development of HCC: 7% had a liver stiffness measurement 
         
consistent with liver cirrhosis and 60% had a high HBV VL at the time of ART start. The 
prevalence of liver cirrhosis among people with HBV in our study is in line with the results of 
a recent meta-analysis, which showed similar estimates across SSA, and did not find 
evidence of a significant difference between HIV-infected and uninfected individuals (Surial 
et al., 2020). Interestingly, most individuals with liver stiffness compatible with cirrhosis did 
not have signs of liver cirrhosis on ultrasound. This finding could be explained by the higher 
sensitivity of elastography to diagnose cases of early, well-compensated cirrhosis, or by the 
impact of schistosomiasis in increasing liver stiffness (Hashim and Berzigotti, 2021). The 
prevalence of additional HCC risk factors was also high in this population: 43% of individuals 
reported unhealthy alcohol use and regular exposure to aflatoxin is widespread in the 
region. The need for HCC surveillance in non-cirrhotic patients treated with potent antiviral 
therapy is debated, as long-term suppression leads to the regression of liver fibrosis and 
cirrhosis and reduces the incidence of HCC (Marcellin et al., 2013, Wandeler et al., 2019). 
However, given the high burden of HCC risk factors in SSA, HCC surveillance 
recommendations will have to be informed by prospective HBV cohorts with long-term HCC 
surveillance, such as the one described here.  
In our cross-sectional analysis, five (2%) HIV/HBV-coinfected individuals had an indication to 
undergo liver CT-scan because of a liver lesion >1cm on ultrasound. In two participants, this 
procedure was able to help exclude an HCC. One patient was lost to follow-up before a CT 
scan could be performed, and in the other two participants, a CT scan was not performed as 
the size of the lesions had reduced in subsequent AUS examinations. None of the 
participants showing liver lesions on AUS had elevated levels of AFP at time of AUS. In 
resource-limited settings, access to 4-phase CT scan to confirm or rule out HCC is limited due 
to the required infrastructure, including consistent power supply, supplies, specific contrast 
         
and syringes, and the needed expertise in using and maintaining the device. Furthermore, 
the 4-phase protocol, which involves complex timing of contrast injection, is rarely done in 
SSA and hence additional training is needed. Finally, the interpretation of contrast 
enhancement during the different phases of the procedure and standardized reporting 
require an experienced radiologist familiar with these procedures. Given the many 
challenges associated with the implementation of 4-phase CT or MRI in low-income 
countries, the use of potential HCC biomarkers should be evaluated to strengthen risk 
stratification and diagnosis of HCC. 
We found a high proportion of individuals with periportal fibrosis, a finding suggestive of 
schistosomiasis. The prevalence of schistosomiasis reaches 88% in endemic parts in Zambia, 
and related non-cirrhotic portal hypertension is a major cause of variceal bleeds in the 
region (Sinkala et al., 2020). Schistosomiasis may potentiate hepatic injury in the presence of 
HBV or hepatitis C virus (HCV) infections and experimental and clinical studies have 
suggested that schistosomiasis promotes the development of HCC (El-Tonsy et al., 2013). 
However, biomolecular mechanism explaining the link between S. mansoni infection and 
HCC are still unknown and it remains unclear whether schistosomiasis needs to be 
considered as an additional risk factor for the development of HCC. The systematic 
assessment of exposure to schistosomiasis should be included in studies assessing risk 
factors for HCC in endemic regions. 
We provide data from one of the first HCC screening initiatives among HBV-infected 
individuals in SSA. The following aspects make this clinical research platform unique in the 
region: (i) Our patients had a comprehensive diagnostic work-up, including HBV virological 
analyses, alcohol assessment and transient elastography, before the initiation of HCC 
screening, (ii) we avoided selection bias by securing the participation of a large majority of 
         
our patients with weekly transport to the radiology department, (iii) ultrasound 
examinations were conducted by one of three experienced radiologists who reported their 
results on a standardized form, (iv) we confirmed the diagnosis of HCC with a state-of-the-
art 4-phase CT scan protocol, and (v) we peformed AFP measurements when stored sampes 
were available at same time of AUS. However, the cross-sectional nature of this analysis and 
the absence of cases of HCC in the first round of ultrasound assessments does not allow us 
to draw any conclusions on the burden of end-stage live-disease in this population. An 
inherent limitation of the use of abdominal ultrasound is its low sensitivity for small tumors, 
which might have led to the under-estimation of the proportion of patients with clinically 
relevant nodules. Furthermore, AFP measurements where only available in 53% of all 
patients. Finally, the characterization of risk factors for liver disease could have been 
improved by the systematic measurement of aflatoxin B1 and schistosomal infection.  
In summary, during the initial phases of an HCC surveillance initiative in urban Zambia, we 
found a high prevalence of liver cirrhosis and periportal fibrosis among adults with HIV/HBV 
coinfection and 2% had liver lesions warranting CT scan. We were able to include the 
majority of patients in our cohorts into the HCC screening program, owing to the high 
dedication of our study staff and the collaboration with a highly motivated tertiary care 
radiology department. Considering the logistical and financial challenges to be addressed, 
for such a program to be sustainable, inclusion of participants based on optimized risk 
stratification and simplification of diagnostic tools will be key. Therefore, the assessment of 
the diagnostic accuracy of AFP and new promising biomarker panels in larger prospective 
cohorts in the region is crucial. As HCC events are expected to occur frequently in young 
people with non-cirrhotic HBV infection in SSA, it will be crucial to assess HCC incidence and 
         
identify related risk factors in prospective studies with systematic surveillance programs, as 
in our Zambian cohort.  
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Figure 1. Main findings at first ultrasound screening (n= 279) 
 
Hepatomegaly was defined as liver diameter >15cm; patterns of periportal fibrosis was 
registered and graded according to the Niamey classification [15]; signs of cirrhosis were 
defined as any of the following: surface nodularity, overall coarse and heterogeneous 
echotexture, atrophy or segmental hypertrophy; steatosis were defined by increased liver 
echogenicity compared to right kidney parenchyma and beam attenuation. 
  
         
Figure 2. Summary of patients with liver lesions. Main characteristics of the five 
patients with liver lesions (Panel A) and radiological examinations (US and 4-phase CT) 
of patient 5 (Panel B) 
 
 
Imaging findings in patient 5: The liver tissue is highly cirrhotic and shows an 
inhomogeneous hypo- and hyperechogenic structure in b-mode ultrasound (A). In the 
         
multiphase CT scan (B-D), the arterial phase (B) reveals a cirrhotic nodular surface of the 
liver (arrow in B), however, there are no focal lesions with an arterial hyperperfusion. 
Comparable to the ultrasound examination, the liver tissue is highly inhomogeneous with 
multiple nodules also in the portal venous (small arrows in C) and the late contrast phase 
(small arrows in D). Due to an elevated portal venous pressure, large portocaval collaterals 
can be seen (dotted arrow in C). 
         
